

# SCIENTIFIC REPORTS



OPEN

## Recruiting a new strategy to improve levan production in *Bacillus amyloliquefaciens*

Jun Feng<sup>1,2,\*</sup>, Yanyan Gu<sup>1,\*</sup>, Yufen Quan<sup>1</sup>, Wei Zhang<sup>1</sup>, Mingfeng Cao<sup>4</sup>, Weixia Gao<sup>1</sup>, Cunjiang Song<sup>1</sup>, Chao Yang<sup>2</sup> & Shufang Wang<sup>3</sup>

Received: 06 January 2015

Accepted: 06 August 2015

Published: 08 September 2015


Microbial levan is an important biopolymer with considerable potential in food and medical applications. *Bacillus amyloliquefaciens* NK- $\Delta$ LP strain can produce high-purity, low-molecular-weight levan, but production is relatively low. To enhance the production of levan, six extracellular protease genes (*bpr*, *epr*, *mpr*, *vpr*, *nprE* and *aprE*), together with the *tasA* gene (encoding the major biofilm matrix protein TasA) and the *pgsBCA* cluster (responsible for poly- $\gamma$ -glutamic acid ( $\gamma$ -PGA) synthesis), were intentionally knocked out in the *Bacillus amyloliquefaciens* NK-1 strain. The highest levan production (31.1 g/L) was obtained from the NK-Q-7 strain ( $\Delta$ *tasA*,  $\Delta$ *bpr*,  $\Delta$ *epr*,  $\Delta$ *mpr*,  $\Delta$ *vpr*,  $\Delta$ *nprE*,  $\Delta$ *aprE* and  $\Delta$ *pgsBCA*), which was 103% higher than that of the NK- $\Delta$ LP strain ( $\Delta$ *pgsBCA*) (15.3 g/L). Furthermore, the NK-Q-7 strain also showed a 94.1% increase in  $\alpha$ -amylase production compared with NK- $\Delta$ LP strain, suggesting a positive effect of extracellular protease genes deficient on the production of endogenously secreted proteins. This is the first report of the improvement of levan production in microbes deficient in extracellular proteases and TasA, and the NK-Q-7 strain exhibits outstanding characteristics for extracellular protein production or extracellular protein related product synthesis.

Microbial levan, one of the two main types of fructan biopolymers, is mainly polymerized via  $\beta$ -(2  $\rightarrow$  6) bonds<sup>1</sup> and has been isolated from Gram-negative bacteria, Gram-positive bacteria and some fungi<sup>2</sup>. Levan has many favourable properties, and is used in variety of industrial applications including in foods, cosmetics and pharmaceuticals<sup>3-5</sup>.

Previous work has revealed that microbial levan is synthesized in the medium by the secreted levan-sucrase (EC: 2.4.1.10) from the sucrose substrate<sup>6</sup>. Microorganisms synthesize higher-molecular-weight levan at the beginning of fermentation, after which the molecule is hydrolyzed to lower-molecular-weight levan products in the presence of the  $\beta$ -2,6-fructofuranoside linkage-hydrolyzing enzyme, levanase<sup>5</sup>.

*Bacillus amyloliquefaciens* NK-1 has the ability to co-produce  $\gamma$ -PGA and levan during fermentation. The *pgsBCA* genes (responsible for  $\gamma$ -PGA synthesis) deletion strain *B. amyloliquefaciens* NK- $\Delta$ LP can produce high-purity levan, with the highest titer observed being 14 g/L<sup>7</sup>. The molecular weight of levan obtained from the NK- $\Delta$ LP strain is around 5 kDa, which is much lower than other reported levan products<sup>8</sup>. The *Bacillus amyloliquefaciens* strain was isolated from fermented food<sup>9</sup>, thus its levan product was supposed to have the potential to be the dietary supplements<sup>10</sup>. However, the low levan production by this strain is unable to meet industrial demands. Therefore, further strain improvement through metabolic engineering is required.


\*Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Nankai University, Tianjin 300071, China. <sup>2</sup>Department of Microbiology, College of Life Science, Nankai University, Tianjin 300071 China. <sup>3</sup>State Key Laboratory of Medicinal Chemical Biology, Nankai University, 94 Weijin Road, Tianjin 300071, China. <sup>4</sup>Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to C.S. (email: songcj@nankai.edu.cn) or C.Y. (email: yang\_chao2008@hotmail.com) or S.W. (email: wangshufang@nankai.edu.cn)



**Figure 1. Metabolic pathways associated with levan biosynthesis in *Bacillus amyloliquefaciens* and engineering strategies for levan production.** The red font indicates the genes deleted in this study and the corresponding deficient products. Metabolite symbols: Sucrose-6P, sucrose-6-phosphate; Bpr, bacillopeptidase F; Epr, extracellular serine protease; Mpr, extracellular metalloprotease; Vpr, extracellular serine protease; NprE, extracellular neutral metalloprotease; AprE, extracellular alkaline serine protease; TasA, major biofilm matrix protein; *pgsBCA*, poly- $\gamma$ -glutamate synthase.

Most of the strategies applied thus far to enhance levan production have been limited to medium optimization or fermentation process improvement<sup>11,12</sup>, and only a few metabolic engineering strategies have been utilized to improve levan production. Senthilkumar *et al.*<sup>13</sup> studied the effect of the disruption of the *Zymomonas mobilis* extracellular sucrose gene (*sacC*) on levan production. The *sacC* gene mutant strain showed three-fold higher levansucrase (SacB) activity than the wild-type strain and the levan titer increased from 15.5 g/L to 21.2 g/L. Similar genetic modification was performed in *Lactobacillus reuteri*, demonstrating that disruption of the sucrose phosphorylase gene *scrP*, (encoding a sucrose hydrolysis enzyme), also increased levan production<sup>14</sup>. Shida *et al.*<sup>15</sup> studied the effects of disrupting the levanase gene *sacC* on levan production in *Bacillus subtilis* 327UH strain. The results showed that there was no difference in the obtained levan yield between the *sacC*-deficient strain and the wild-type strain; however, the polymerization degree of levan obtained from the *sacC*-deficient strain was approximately three times higher compared with that from the wild-type strain. Over-expression of the *sacB* gene is another method for improving levan production. Ananthalakshmy *et al.*<sup>16</sup> expressed the *sacB* gene by using the pLSD19 plasmid in the sucrose mutant *Zymomonas mobilis* Zsuc1 strain and found that levan production increased from 5 g/L to 10.7 g/L compared with the wild-type strain.

In the current study, we proposed a new strategy for metabolic engineering of the *B. amyloliquefaciens* NK-1 strain to improve levan production. TasA is the main protein in biofilm matrix<sup>17,18</sup>. The extracellular matrix surrounds the cells and might block the secretion of levansucrase. Previous works demonstrated that the *tasA* gene deletion strain could only form deficient biofilm<sup>17</sup>. The *tasA* gene was deleted in this work to determine its effects on levan production. *Bacillus* can produce high level of extracellular proteases to degrade the extracellular protein for cell use<sup>19</sup>. We speculated that deleting protease genes can expect to find other extracellular proteins more stable. Thus, we decided to delete the extracellular protease genes to improve levan production. In our previous work, we found that NK-1 strain could co-produce  $\gamma$ -PGA and levan simultaneously; moreover, their purification procedures are similar. Thus, *pgsBCA* genes deletion may increase levan purity as well as its production. A schematic of this proposed genetically engineered metabolic pathway of *B. amyloliquefaciens* NK-1 is shown in Fig. 1. We aimed to improve levan production by carrying out the above-mentioned three tasks: (1) delete the *tasA* gene to make the biofilm formation deficient; (2) delete six extracellular proteases genes *bpr*<sup>20,21</sup>, *epr*<sup>22</sup>, *mpr*<sup>23,24</sup>, *vpr*<sup>25</sup>, *nprE*<sup>26</sup> and *aprE*<sup>27,28</sup>, to decrease the degradation of the levansucrase; and (3) delete the *pgsBCA* cluster to block the  $\gamma$ -PGA synthesis pathway and obtain a higher purity and yield of the levan product. The final engineered NK-Q-7 strain could produce 31.1 g/L levan in flask, which was 103% higher compared with the production in the NK- $\Delta$ LP strain.




**Figure 2. Confirmation of gene deletions via PCR.** Chromosomal DNA served as the template for amplification. Lane M: DNA marker III; Lane WT: strains amplified with relevant detection primers using *B. amyloliquefaciens* NK-1 chromosomal DNA as the template; Lane MT: strains amplified with the relevant detection primers using chromosomal DNA from the gene deletion strains' as the template.

## Results

**Construction of marker-less gene deletion mutants.** In this work, we sought to improve levan production in a *B. amyloliquefaciens* strain by deleting the *tasA* gene, extracellular protease genes and the *pgsBCA* cluster. For the preferential effect behavioral test on  $\gamma$ -PGA production, we first deleted the *tasA* gene and then sequentially deleted the six extracellular protease genes *bpr*, *epr*, *mpr*, *vpr*, *nprE* and *aprE* in the NK-1 strain. The target strains were designated NK-P-X (X = 1–7). Next, the  $\gamma$ -PGA synthetase cluster *pgsBCA* was deleted from the NK-P-X strains, and the resultant  $\gamma$ -PGA-deficient strains were designated NK-Q-X.

We constructed these gene deletion mutants via a marker-less knockout method. This method is based on using the *upp* gene, which encodes uracil-phosphoribosyl-transferase, as the counter-selectable marker. The *upp* cassette and 5-fluorouracil (5-FU) selection were used to identify marker-less gene deletions<sup>29</sup>. According to the PCR results shown in Fig. 2 and the DNA sequencing results, we confirmed that the gene mutant strains had been successfully constructed.

**The effects of *tasA* gene deletion on biofilm formation.** Our previous work showed that *B. amyloliquefaciens* NK-1 could form structurally complex biofilms<sup>30</sup>. Genetic, biochemical and cytological evidences suggested that this complex extracellular matrix is mainly composed of TasA and Eps and the absence of TasA or Eps results in a residual matrix<sup>17,31</sup>. Levan and  $\gamma$ -PGA also contribute to bacterial biofilm formation, cross-linking with other components to make the biofilm complete<sup>32,33</sup>. Biofilm formation by the NK-1, NK-P-1, NK-Q-1 and NK- $\Delta$ LP strains was observed and the results were shown in Fig. 3. As expected, the NK-1 strain was able to form a complete pellicle, whereas the *tasA* gene deletion NK-P-1 strain could only form a deficient, incomplete pellicle. Unexpectedly, neither of the *pgsBCA* genes deletion strains (NK-Q-1 and NK- $\Delta$ LP) could form a pellicle. This result indicates that  $\gamma$ -PGA is the main component of the biofilm formed by the  $\gamma$ -PGA-producing strain and that the strain with deficient  $\gamma$ -PGA production could not form a biofilm.




**Figure 3.** Cell pellicle formation in the *B. amyloliquefaciens* NK-1, *B. amyloliquefaciens* NK-P-1, *B. amyloliquefaciens* NK-Q-1 and *B. amyloliquefaciens* NK- $\Delta$ LP strains. Cells were cultured at 30°C for 72 h in MSgg broth in a six-well microtiter dish.

**Comparison of  $\gamma$ -PGA production between *B. amyloliquefaciens* NK-1 and the mutant NK-P-X strains in flask culture.** The effects of the deletion of *tasA* and the six-extracellular protease genes on  $\gamma$ -PGA production were characterized in this work. The  $\gamma$ -PGA fermentation results obtained from *B. amyloliquefaciens* NK-1 and the gene deletion mutant strains are shown in Fig. 4.  $\gamma$ -PGA production remained unchanged after deleting the *tasA*, *bpr*, *epr* and *mpr* genes. However, the NK-P-5 strain, harboring further deletion of the *vpr* gene, showed increased  $\gamma$ -PGA production. The NK-P-5 strain exhibited the highest  $\gamma$ -PGA yield, which was a 24.2% increase compared with the NK-1 strain, leading to a titer of 4.62 g/L, compared with 3.72 g/L for the control.  $\gamma$ -PGA production was lower in the strains in which the *nprE* and *aprE* genes were deleted.  $\gamma$ -PGA production from the NK-P-7 strain was 2.19 g/L, which was 47.4% lower than in the NK-P-5 strain. Moreover, the dry cell weight (DCW) of the NK-P-7 strain was lower than other strains, and this strain was observed to enter the cell decline phase earlier.


**Comparison of levan production between the *B. amyloliquefaciens* NK- $\Delta$ LP and mutant NK-Q-X strains in flask culture.** To evaluate the effect of the accumulation of gene-targeted *B. amyloliquefaciens* mutants on levan production, flask culture of *B. amyloliquefaciens* NK- $\Delta$ LP and the mutant strains was undertaken under identical conditions. We sought to delete the *tasA* gene for two reasons: (1) disruption of *tasA* can conserve energy and favor the production of levan via the metabolic flux; (2) Cells in biofilms are embedded in the extracellular matrix, which contains TasA, the major matrix protein. We speculated that by removing TasA, which is known to be bound to cells<sup>17</sup>, we may influence the export of extracellular levansucrase. Therefore it might have been possible that lack of TasA increases the production of levan. The fermentation results shown in Fig. 5a indicated that the deletion of *tasA* gene did affect levan production. The NK-Q-1 strain showed a slight 14.4% increase in levan production (17.5 g/L) compared with the NK- $\Delta$ LP strain (15.3 g/L).

Levan is synthesized in the medium by secreted levansucrase. We reasoned that the lack of extracellular proteases might make the extracellular levansucrase more stable, thereafter improving levan





**Figure 4.**  $\gamma$ -PGA fermentation results in the *B. amyloliquefaciens* NK-1 and mutant NK-P-X strains after 48 h of cultivation. Values represent the means  $\pm$  SD. Asterisks indicate significant difference from the NK-1 strain ( $P < 0.05$ ). All cultures were repeated at least five times.




**Figure 5.** Levan and  $\alpha$ -amylase fermentation results in the *B. amyloliquefaciens* NK- $\Delta$ LP and mutant NK-Q-X strains. (a) Comparison of levan production and dry cell weights between NK- $\Delta$ LP and the mutant strains after 48 h of cultivation. (b) Comparison of  $\alpha$ -amylase production and dry cell weights between NK- $\Delta$ LP and the mutant strains after 48 h of cultivation. Values represent the means  $\pm$  SD. Asterisks indicate significant difference from the NK- $\Delta$ LP strain ( $P < 0.05$ ). All cultures were repeated at least five times.

production in the medium. As shown in Fig. 5a, the extracellular protease gene deletion strains NK-Q-2 and NK-Q-7 exhibited levan production increase. Among these strains, NK-Q-7 displayed the highest increase in productivity (31.1 g/L), resulting in 103% improvement of levan production compared with the NK- $\Delta$ LP control. The molecular weight of levan obtained from NK-Q-7 strain was 4, 600 Da, and its purity reached  $94.1 \pm 1.3\%$ . However, not all of the mutant strains showed improved levan production; the NK-Q-4 and NK-Q-5 strains displayed decreases of 21.3% and 32.4% in levan production, respectively.

**Comparison of  $\alpha$ -amylase production between *B. amyloliquefaciens* NK- $\Delta$ LP and the mutant NK-Q-X strains in flask culture.** To evaluate the effect of the gene deletions on extracellular protein

Strains	Extracellular protease activity (%)
NK- $\Delta$ LP	100 $\pm$ 12.3
NK-Q-1	104 $\pm$ 1.7
NK-Q-2	62.1 $\pm$ 3.3
NK-Q-3	50.5 $\pm$ 1.4
NK-Q-4	55.6 $\pm$ 17.4
NK-Q-5	54.6 $\pm$ 2.0
NK-Q-6	44.2 $\pm$ 0.7
NK-Q-7	14.3 $\pm$ 1.2*

**Table 1.** Comparison of extracellular protease activity between the *Bacillus amyloliquefaciens* NK- $\Delta$ LP and *Bacillus amyloliquefaciens* NK-Q-X strains in levan fermentation medium. All cultures were repeated at least five times. Asterisks indicate significant difference from the NK- $\Delta$ LP strain ( $P < 0.05$ ).



**Figure 6.** GPC results for  $\gamma$ -PGA and levan products. (a) GPC spectrum of  $\gamma$ -PGA obtained from *B. amyloliquefaciens* NK-1 and (b) GPC spectrum of levan obtained from *B. amyloliquefaciens* NK- $\Delta$ LP.

production, we also determined the  $\alpha$ -amylase production. The results regarding  $\alpha$ -amylase production are shown in Fig. 5b. Consistent with the levan fermentation results (Fig. 5a), the NK-Q-7 strains showed significantly increased  $\alpha$ -amylase production to approximately 0.66 U/mL of amylase activity, which was 94.1% higher compared with the NK- $\Delta$ LP strain.

**Determination of extracellular protease activities in the *B. amyloliquefaciens* NK-Q-X strains.** We further analyzed extracellular protease activities in the NK-Q-X strains at the end of stationary phase during the levan fermentation process, and the results are presented in Table 1. The protease activities of NK- $\Delta$ LP and NK-Q-1 were comparable, indicating that the deletion of *tasA* had no effect on cell protease activity. The *bpr* gene deletion strain NK-Q-2 showed a 38% decrease compared with the NK- $\Delta$ LP strain, whereas the NK-Q-3 strain, in which both *bpr* and *epr* were deleted, exhibited an approximately a 50% decrease in protease activities. Surprisingly, and in contrast to previous studies, the detected protease activities was unchanged after deletion the *mpr* and *vpr* genes. However, the strain without *nprE* and *aprE* gene showed further decreases in protease activity; protease activity was decreased by 56% in NK-Q-6 and by a notable 86% in NK-Q-7 compared with the NK- $\Delta$ LP strain.

## Discussion

*B. amyloliquefaciens* NK-1 is derived from the LL3 strain, which was isolated from fermented food (Korea bibimbap paste)<sup>9</sup>, thus it is safe for human beings. In our previous work, we found that the NK-1 strain could co-produce  $\gamma$ -PGA and levan simultaneously (Fig. 6a). After deleting the *pgsBCA* cluster, the obtained NK- $\Delta$ LP strain could not produce  $\gamma$ -PGA, and the remaining product mainly consisted of levan, at a purity reaching 92.7% (Fig. 6b)<sup>7</sup>. From our previously work, we determined that the bacteria could produce levan products of two different molecular weights. Higher-molecular-weight levan is produced at early timepoints and is then hydrolyzed to lower-molecular-weight levan by levanase, and the low-molecular-weight levan is dominant after 48 h of fermentation<sup>7</sup>. The levan molecular weight obtained from the NK- $\Delta$ LP strain was mostly around 5 kDa<sup>7</sup>, which is significantly lower than other reported levan products<sup>8</sup>. However, levan production needs to be improved to meet the requirements for industrial application<sup>34</sup>.

We deleted the *tasA* gene from the NK-1 strain, and the resulting NK-P-1 strain could form incomplete biofilms, whereas the *tasA* and *pgsBCA* double-deletion NK-Q-1 strain could not form a biofilm (Fig. 3). We further studied the effects of these deletions on levan synthesis. The NK-Q-1 strain showed

a 14.4% increase in levan production compared with the NK- $\Delta$ LP strain (Fig. 5a). Unlike our expected, the deletion of *tasA* gene had little effect on levan production.

*Bacillus* species can produce high levels of extracellular proteases to degrade secreted heterologous proteins<sup>19</sup>. Many protease-deficient strains have been constructed and display favorable features for the improvement of heterologous protein production. *B. subtilis* WB600 is a strain that is deficient in six-extracellular-protease ( $\Delta nprE$ ,  $\Delta nprB$ ,  $\Delta aprE$ ,  $\Delta epr$ ,  $\Delta mpr$ ,  $\Delta bpr$ ) and shows improved production of heterologously expressed  $\beta$ -lactamase, streptokinase and the antidigoxin single-chain antibody fragment over the wild-type strain<sup>35–37</sup>. Although many works have focused on the effect of extracellular-protease-deficiency on heterologous proteins, few efforts have been made to study its effect on endogenous protein production. We hypothesized that the extracellular proteases degrade not only misfolded proteins but also degraded proteins (which still exhibit low catalytic activity) or even fully-functional proteins in the end stage of fermentation when nitrogen is limited. Based on this hypothesis, we aimed to improve levan production by knocking out the microbe's extracellular protease genes. Levan is produced by the secreted levansucrase SacB, and extracellular proteases may affect the amount and activity of SacB to some degree, decreasing levan production. And the extracellular-proteases-deficient strains probably exhibit increased production of extracellular protein including SacB, thereafter increase the production of levan. The NK-1 strain exhibits seven extracellular proteases: Bpr, Epr, Mpr, Vpr, NprE, AprE and WprA<sup>38</sup>, and we aimed to delete all of these associated genes. However, we failed to delete the *wprA* gene for unknown reasons. The other six genes were successfully deleted.

The six-gene-deletion NK-Q-7 strain showed the highest levan production, presenting increases of approximately about 102% and 78% compared with the NK- $\Delta$ LP and NK-Q-1 strains, respectively. We speculated that the increase of levan production was related to the increase of SacB production, and the deletion of extracellular protease genes improved the production of extracellular protein-SacB. To evaluate our speculation, we further determined the effect of gene deletions on another endogenous product  $\alpha$ -amylase (a secreted *Bacillus* protein). The NK-Q-7 strain showed the highest yield of  $\alpha$ -amylase as well, with production being increased by 96% and 74%, compared with the NK- $\Delta$ LP and NK-Q-1 strains, respectively. These results demonstrate that the deficiency of extracellular protease genes indeed increase the cells' production of their own secreted proteins. Despite exhibiting highest production, the DCW of NK-Q-7 was the lowest among these strains. Additionally, more frequent cell lysis was detected in the end stage of fermentation and the number of living cells was  $28 \pm 9\%$  less than that of the control NK- $\Delta$ LP strain. Another interesting phenomenon observed in this strain was the shorter time (24h) required for the organism to adapt to the high carbon source conditions (in the levan seed culture) compared with other six strains (30–36h) when transferred from incubation in LB medium. This particular feature might offset the early cell lysis in the end stage of fermentation.

We also characterized the extracellular protease activity of the NK-Q-X strains in levan fermentation medium. Consistent with our hypothesis, the extracellular protease activity of the NK-Q-7 strain showed a dramatic decrease to approximately 14.3% of that in the NK-1 strain (Table 1). However, this extracellular protease activity was still higher than in other previously reported strains, such as *B. subtilis* GB2054 (with inactivation of two extracellular proteases, NprE and Apr, and no detectable extracellular protease activity)<sup>39</sup> and *B. subtilis* WB700 (with inactivation of seven extracellular proteases, NprE, NprB, AprE, Epr, Mpr, Bpr and Vpr, and decreased extracellular protease activity to approximately 0.14% of that in the wild-type strain)<sup>40</sup>. This difference may be attributable to the applied cell culture conditions. However, not all of the mutant strains showed increased levan production. For example, the NK-Q-4 and NK-Q-5 strains were deficient in extracellular protease activity, yet showed reduced levan production. The *mpr* and *vpr* gene deletions might be harmful to levan production.

As the production of TasA and extracellular proteases consumes a great deal of energy, we also studied the effect of these gene deletions on  $\gamma$ -PGA production. However, their deletions had little effect on  $\gamma$ -PGA production, and only the NK-P-5 strain exhibited a slight increase in  $\gamma$ -PGA production (Fig. 4).

In summary, we proposed a new strategy for improving levan production in this work. We deleted the *tasA* gene, six extracellular protease genes and the *pgsBCA* cluster. The resulting NK-Q-7 strain produced 31.1 g/L levan, which was 103% higher than the production in the NK- $\Delta$ LP control strain. The NK-Q-7 also yielded 96% more  $\alpha$ -amylase. These results indicate that NK-Q-7 strain could be utilized as a candidate cell factory for secreted protein production or secreted protein related product synthesis.

## Methods

**Strains, plasmids and growth conditions.** All of the strains and plasmids used in this work are listed in Table 2. The *B. amyloliquefaciens* NK-1 strain was a derivative of the LL3 strain with the endogenous plasmid pMC1 and the *upp* gene deleted<sup>41–42</sup>. The *B. amyloliquefaciens* NK- $\Delta$ LP strain was a derivative of the NK-1 strain with the *pgsBCA* cluster deleted. *Escherichia coli* DH5 $\alpha$  was used for plasmid propagation and transformation. The *dam*- and *dcm*- deficient *E. coli* strain GM2163 was used for plasmid demethylation.

For routine strain construction and maintenance, the *B. amyloliquefaciens* and *E. coli* strains were grown at 37°C in Luria-Bertani (LB) medium. To produce  $\gamma$ -PGA, the *B. amyloliquefaciens* strains were cultured at 37°C and 180 rpm, for 48 h in  $\gamma$ -PGA fermentation medium<sup>43</sup>. To produce levan, *B. amyloliquefaciens* strains were cultured at 37°C and 180 rpm, for 48 h in levan fermentation medium (pH 6.0), which containing 250.9 g/L sucrose, 2.6 g/L urea, 0.62 g/L MgSO<sub>4</sub>, 8.16 g/L KH<sub>2</sub>PO<sub>4</sub>, 18.24 g/L

Strains and plasmids	Relevant genotype and characteristics	Source
<b>Strains</b>		
<i>B. amyloliquefaciens</i> LL3	wild type	(9)
<i>B. amyloliquefaciens</i> NK-ΔLP	NK-1 derivative, Δ <i>pgsBCA</i>	This lab
<i>B. amyloliquefaciens</i> NK-1	LL3 derivative, Δ <i>pMC1</i> , Δ <i>upp</i>	(42)
<i>B. amyloliquefaciens</i> NK-P-1	NK-1 derivative, Δ <i>tasA</i>	This work
<i>B. amyloliquefaciens</i> NK-P-2	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i>	This work
<i>B. amyloliquefaciens</i> NK-P-3	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i> , Δ <i>epr</i>	This work
<i>B. amyloliquefaciens</i> NK-P-4	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i> , Δ <i>epr</i> , Δ <i>mpr</i>	This work
<i>B. amyloliquefaciens</i> NK-P-5	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i> , Δ <i>epr</i> , Δ <i>mpr</i> , Δ <i>vpr</i>	This work
<i>B. amyloliquefaciens</i> NK-P-6	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i> , Δ <i>epr</i> , Δ <i>mpr</i> , Δ <i>vpr</i> , Δ <i>nprE</i>	This work
<i>B. amyloliquefaciens</i> NK-P-7	NK-1 derivative, Δ <i>tasA</i> , Δ <i>bpr</i> , Δ <i>epr</i> , Δ <i>mpr</i> , Δ <i>vpr</i> , Δ <i>nprE</i> , Δ <i>aprE</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-1	NK-P-1 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-2	NK-P-2 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-3	NK-P-3 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-4	NK-P-4 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-5	NK-P-5 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-6	NK-P-6 derivative, Δ <i>pgsBCA</i>	This work
<i>B. amyloliquefaciens</i> NK-Q-7	NK-P-7 derivative, Δ <i>pgsBCA</i>	This work
<i>E. coli</i> DH5α	F <sup>-</sup> , ϕ80 <i>dlacZ</i> Δ <i>M1</i> , Δ( <i>lacZYA-argF</i> )U169, <i>deoR</i> , <i>recA1</i> , <i>endA1</i> , <i>hsdR17</i> (r <sub>k</sub> <sup>-</sup> , m <sub>k</sub> <sup>+</sup> ), <i>phoA</i> , <i>supE44</i> , λ <sup>-</sup> <i>thi-1</i> , <i>gyrA96</i> , <i>relA1</i>	This lab
<i>E. coli</i> GM2163	F <sup>-</sup> , <i>ara-14</i> <i>leuB6</i> <i>thi-1</i> <i>fluA31</i> <i>lacY1</i> <i>tsx-78</i> <i>galK2</i> <i>galT22</i> <i>supE44</i> <i>hisG4</i> <i>rpsL</i> 136 ( <i>Str</i> <sup>r</sup> ) <i>xyl-5</i> <i>mtl-1</i> <i>dam13::Tn9</i> (Cam <sup>r</sup> ) <i>dcm-6</i> <i>mcrB1</i> <i>hsdR2</i> <i>mcrA</i>	This lab
<b>Plasmids</b>		
pKSV7	Shuttle vector, temperature-sensitive (ts) replication origin, Amp <sup>r</sup> (gram-negative) and Cm <sup>r</sup> (gram-positive)	(45)
p-KSU	pKSV7-derivation with <i>upp</i> gene	(46)
pKSV7-ΔLP	p-KSU-derivation with deletion fragment of <i>pgs operon</i>	This lab
pKSV7-Δ <i>tasA</i>	p-KSU-derivation with deletion fragment of <i>tasA</i>	This work
pKSV7-Δ <i>bpr</i>	p-KSU-derivation with deletion fragment of <i>bpr</i>	This work
pKSV7-Δ <i>epr</i>	p-KSU-derivation with deletion fragment of <i>epr</i>	This work
pKSV7-Δ <i>mpr</i>	p-KSU-derivation with deletion fragment of <i>mpr</i>	This work
pKSV7-Δ <i>vpr</i>	p-KSU-derivation with deletion fragment of <i>vpr</i>	This work
pKSV7-Δ <i>nprE</i>	p-KSU-derivation with deletion fragment of <i>nprE</i>	This work
pKSV7-Δ <i>aprE</i>	p-KSU-derivation with deletion fragment of <i>aprE</i>	This work

**Table 2. Strains and plasmids used in this study.**

K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, 1 mM FeSO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, 1 mM MnSO<sub>4</sub> and 1 mM ZnCl<sub>2</sub>. To produce α-amylase, the *B. amyloliquefaciens* strains were cultured at 37°C and 180 rpm, for 48 h in α-amylase fermentation medium (pH 7.0), containing 10 g/L soluble starch, 2 g/L tryptone, 1 g/L KH<sub>2</sub>PO<sub>4</sub>, 2.5 g/L Na<sub>2</sub>HPO<sub>4</sub>, 2 g/L (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1 g/L NaCl, 0.05 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O and 0.05 g/L CaCl<sub>2</sub><sup>44</sup>.

The concentrations of the antibiotics used in this work were as follow: 100 μg/mL ampicillin, 5 μg/mL chloramphenicol. The final concentration of 5-FU was 100 μg/mL.

**DNA manipulation and plasmid construction.** To construct the gene deletion vectors, the temperature-sensitive pKSU plasmid was used, which was derived from the pKSV7 plasmid<sup>45,46</sup>. The *upp* expression cassette was ligated to the pKSV7 plasmid as a reverse selection marker. All of the oligonucleotide primers used in this work are listed in Table 3. We decided to delete eight genes: *tasA*, *aprE*, *bpr*, *epr*, *mpr*, *nprE*, *vpr* and *pgsBCA*. The upstream and downstream fragments of the genes targeted for deletion were amplified with PrimeSTAR HS DNA polymerase (Takara Bio, Japan) using the primers N-SF/N-SR and N-XF/N-XR, respectively (N represents the relevant gene name). The obtained upstream and downstream DNA fragments were joined via overlap-PCR. The combined fragments were first ligated to the pMD19-T simple vector (Takara Bio, Japan). All of the constructed plasmids were verified through DNA sequencing (BGI, China). They were then restricted by endonucleases *Sal* I and *Bam*H I and ligated



Primers	Sequence (5'-3')
tasA-SF	CCC <u>GGATCC</u> ACTCTCAAATACATCAGACAAATAG
tasA-SR	CGTTCAGGAACGTTCTTGCTTTTTTGCTGTCTAATGTTTC
tasA-XF	ACAGCAAAAAGCAAGAACGTTCTGAACGATAATACATC
tasA-XR	GGG <u>GTCGAC</u> GAATTTTTTCGCATGTTCAAACATT
tasA-SS	GA CTGACGTCATGAGCTGCTGGGTTTTT
tasA-XX	CCAAGTTCTTTTTCACCGGGAACGCC
bpr-SF	CCCC <u>GGATCC</u> TAACGCCCTTAAACGAAATCT
bpr-SR	TTATTTTTACATTTCTTTTTCTTTTTTCATAGTCTGCCTC
bpr-XF	ATGAAAAAGAAAAAGAAATGTGAAAAATAACAAGAC
bpr-XR	CCCC <u>GTCGACT</u> TACTGAACGTCAC TCATATC
bpr-SS	TAGACACGATTTTCAGCGTGATCC
bpr-XX	GCTCGGAGGCTATTCAGTTGCGTAT
epr-SF	CGCG <u>GATCCC</u> AGGGATGGACAAGAAC
epr-SR	TAAGCGCTCGTATTCTGTTCTCGTTACTGCAGG
epr-XF	CAGTAACGAGAACGAATACGAGCGCTTATTGG
epr-XR	AGGCG <u>GTCGACA</u> AAAGCGGAGGAGAAATACAG
epr-SS	GCGGGTTTATCCTGTCTTAATCGG
epr-XX	GGCACCGTTATTTCTACAGCCTGG
mpr-SF	CCC <u>GGATCC</u> ACTCTCAAATACATCAGACAAATAG
mpr-SR	CGTTCAGGAACGTTCTTGCTTTTTTGCTGTCTAATGTTTC
mpr-XF	ACAGCAAAAAGCAAGAACGTTCTGAACGATAATACATC
mpr-XR	GGG <u>GTCGAC</u> GAATTTTTTCGCATGTTCAAACATT
mpr-SS	GA CTGACGTCATGAGCTGCTGGGTTTTT
mpr-XX	CCAAGTTCTTTTTCACCGGGAACGCC
vpr-SF	CCCC <u>GGATCC</u> TAACGCCCTTAAACGAAATCT
vpr-SR	TTATTTTTACATTTCTTTTTCTTTTTTCATAGTCTGCCTC
vpr-XF	ATGAAAAAGAAAAAGAAATGTGAAAAATAACAAGAC
vpr-XR	CCCC <u>GTCGACT</u> TACTGAACGTCAC TCATATC
vpr-SS	TAGACACGATTTTCAGCGTGATCC
vpr-XX	GCTCGGAGGCTATTCAGTTGCGTAT
nprE-SF	CCCC <u>GGATCC</u> TAACGCCCTTAAACGAAATCT
nprE-SR	TTATTTTTACATTTCTTTTTCTTTTTTCATAGTCTGCCTC
nprE-XF	ATGAAAAAGAAAAAGAAATGTGAAAAATAACAAGAC
nprE-XR	CCCC <u>GTCGACT</u> TACTGAACGTCAC TCATATC
nprE-SS	TAGACACGATTTTCAGCGTGATCC
nprE-XX	GCTCGGAGGCTATTCAGTTGCGTAT
aprE-SF	CCCC <u>GGATCC</u> TAACGCCCTTAAACGAAATCT
aprE-SR	TTATTTTTACATTTCTTTTTCTTTTTTCATAGTCTGCCTC
aprE-XF	ATGAAAAAGAAAAAGAAATGTGAAAAATAACAAGAC
aprE-XR	CCCC <u>GTCGACT</u> TACTGAACGTCAC TCATATC
aprE-SS	TAGACACGATTTTCAGCGTGATCC
aprE-XX	GCTCGGAGGCTATTCAGTTGCGTAT

**Table 3. Primers used in this study.** The restriction enzyme cleavage sites are underlined.

into the pKSU vector digested with the same enzymes, respectively. Finally the generated gene deletion plasmids were designated pKSV7- $\Delta$ N.

**Construction of gene knockout mutant strains.** To carry out multiple gene deletions in a single strain, a modified marker-less gene deletion method was used to construct the gene knockout mutant

strains<sup>29,46</sup>. The primers N-SS and N-XX (N represents the relevant gene name) were used to determine the gene deletion mutants via PCR. We deleted the *tasA*, *bpr*, *epr*, *mpr*, *vpr*, *nprE* and *aprE* genes in turn from the NK-1 strain. The gene disruption mutants were designated *B. amyloliquefaciens* NK-P-1, NK-P-2, NK-P-3, NK-P-4, NK-P-5, NK-P-6 and NK-P-7, respectively. We further deleted the *pgsBCA* cluster (for  $\gamma$ -PGA synthesise) from the NK-P-X strains (X represents the numbers 1–7). The resulting seven  $\gamma$ -PGA-deficient strains were designated NK-Q-X.

**Production of  $\gamma$ -PGA, levan and  $\alpha$ -amylase in flask culture.** For  $\gamma$ -PGA production, single colonies of the *B. amyloliquefaciens* NK-P-X strains were transferred to 50 mL of  $\gamma$ -PGA fermentation medium. After 18 h of incubation at 37 °C and 180 rpm, 1 mL of the cultures was transferred to 100 mL of fermentation medium in shaking flasks and then fermented for 48 h.

The *B. amyloliquefaciens* NK-Q-X strains were used for levan and  $\alpha$ -amylase production. As the cell growth rates in the levan fermentation medium and the  $\alpha$ -amylase fermentation medium were lower than in the  $\gamma$ -PGA fermentation medium, the seed culture times were extended to 24 h–40 h. All cultures were repeated at least five times.

**Enzyme assays.**  $\alpha$ -amylase activity was measured via a modified dinitrosalicylic acid (DNS) method, which was based on the amount of reducing sugars released from soluble starch<sup>47</sup>. A mixture (pH 5.9) containing 1% soluble starch and 0.05 M sodium citrate buffer was heated at 40 °C for 10 min in a water bath. Then, 0.1 mL of culture extract was added to the substrate and incubation was continued at 40 °C for 30 min with gentle shaking. The reaction was subsequently stopped by adding 2 mL of the DNS reagent, after which the reaction was heated at 100 °C for 10 min, and its absorbance was measured at 540 nm. A glucose standard curve was used to determine  $\alpha$ -amylase activity. One unit (U) of  $\alpha$ -amylase activity was defined as the amount of enzyme that liberated one micromole of reducing sugar in one minute under the assay conditions.

Protease activity in the supernatant of the levan fermentation medium at the end of the stationary phase was measured via a modified casein digestion method<sup>48</sup>. One milliliter of 1% casein solution in 0.2 M Tris buffer (pH 8.5) was incubated with 1 mL of test culture for 30 min at 37 °C. The reaction was stopped by the addition of 2 mL of 10% trichloroacetic acid (TCA) solution. After centrifugation at 1000 rpm for 5 min, 1 mL of the supernatant was reacted with the Folin-reagent (Dingguo, China). The protease activity was determined from the absorbance of the reaction at 680 nm. The protease activity determined for NK- $\Delta$ LP in levan fermentation medium was defined as 100%.

**Biofilm formation.** For the analysis of pellicle formation, the NK-1, NK-P-1, NK-Q-1 and NK- $\Delta$ LP strains were cultured on LB agar for 18 h and subsequently incubated in LB broth to an OD<sub>600</sub> of 1.0. Next, 10  $\mu$ L aliquots of the cultures were added to 10 mL of MSgg broth<sup>17</sup> in a six-well microtitre dish. The dishes were incubated at 30 °C for 72 h without agitation, and the pellicles that formed were photographed by a digital camera equipped with a close-up lens (Canon, Tokyo, Japan).

**Analytical procedures.** The optical density (OD) of the cultures was measured with a SHIMADZU UV-1800 spectrophotometer (Kyoto, Japan). The dry cell weight was determined from 100 mL of broth, and the cells were harvested via centrifugation and dried at 50 °C for 24 h to a constant weight after washed with distilled water.  $\gamma$ -PGA was purified by a previously described method<sup>9,49</sup>. The procedure for the purification of levan was similar to that for  $\gamma$ -PGA, with the exception of the use a 3500 MW dialysis bag following the precipitated of levan with four-fold volumes the cold ethanol. The molecular weight of the levan was determined by a gel permeation chromatography (GPC) system<sup>42</sup>. An Alltech system controller (Alltech Associates Inc., US) with a Shodex KW804 column (Showa Denko KK, Japan) and a refractive index (RI) detector (Schambeck SFD GmbH, Germany) were used. 0.25 mol/L NaNO<sub>3</sub> was used as the mobile phase with a flow rate of 0.6 mL/min. Shodex Pullulan-82 standards were used to construct the calibration curve. To measure the levan product purity, 50 mg levan product was hydrolyzed by 6 mol/L HCl at 100 °C for 15 min. The optical density at 291 nm was measured by a SHIMADZU UV-1800 spectrophotometer (Kyoto, Japan) to determine the concentration of fructose in the hydrolyzate<sup>50</sup>. The fructose standards were used to construct the calibration curve. The number of the monosaccharide (N) in levan product was defined as:  $N \approx \frac{Mw(levan)}{162}$ . The purity of levan (%) = fructose concentration (%) \*  $\left(\frac{N+1}{N}\right)$ . The living cells were detected by the optical microscope (XSP-8CA, Shanghai, China) and the methylene blue dye after 48 h of cultivation.

## References

- Han, Y. W. Microbial levan. *Adv. Appl. Microbiol.* **35**, 171–194 (1990).
- Velázquez-Hernández, M. L. *et al.* Microbial fructosyltransferases and the role of fructans. *J. Appl. Microbiol.* **106**, 1763–1778 (2009).
- Yamamoto, Y. *et al.* *In vitro* digestibility and fermentability of levan and its hypocholesterolemic effects in rats. *J. Nutr. Biochem.* **10**, 13–18 (1999).
- Yoo, S. H., Yoon, E. J., Cha, J. & Lee, H. G. Antitumor activity of levan polysaccharides from selected microorganisms. *Int. J. Biol. Macromol.* **34**, 37–41 (2004).

5. Shih, I. L., Chen, L. D. & Wu, J. Y. Levan production using *Bacillus subtilis* natto cells immobilized on alginate. *Carbohydr. Polym.* **82**, 111–117 (2010).
6. Dedonder, R. Levansucrase from *Bacillus subtilis*. *Method. Enzymol.* **8**, 500–505 (1966).
7. Feng, J. *et al.* Construction of a *Bacillus amyloliquefaciens* strain for high purity levan production. *FEMS. Microbiol. Lett.* (2015). doi: 10.1093/femsle/fnv079
8. Ghazi, I. *et al.* Purification and kinetic characterization of a fructosyltransferase from *Aspergillus aculeatus*. *J. Biotechnol.* **128**, 204–211 (2007).
9. Cao, M. F. *et al.* Glutamic acid independent production of poly- $\gamma$ -glutamic acid by *Bacillus amyloliquefaciens* LL3 and cloning of *pgsBCA* genes. *Bioresour. Technol.* **102**, 4251–4257 (2011).
10. Huang, M. Y. *et al.* High-yield levan produced by *Bacillus licheniformis* FRI MY-55 in high-sucrose medium and its prebiotic effect. *J. Pure. Appl. Microbiol.* **7**, 1585–1599 (2013).
11. Silbir, S., Dagbagli, S., Yegin, S., Baysal, T. & Goksungur, Y. Levan production by *Zymomonas mobilis* in batch and continuous fermentation systems. *Carbohydr. Polym.* **99**, 454–461 (2014).
12. Wu, F. C., Chou, S. Z. & Shih, I. L. Factors affecting the production and molecular weight of levan of *Bacillus subtilis* natto in batch and fed-batch culture in fermenter. *J. Taiwan. Inst. Chem. E.* **44**, 846–853 (2013).
13. Senthilkumar, V., Rameshkumar, N., Busby, S. J. W. & Gunasekaran, P. Disruption of the *Zymomonas mobilis* extracellular sucrose gene (*sacC*) improves levan production. *J. Appl. Microbiol.* **96**, 671–676 (2004).
14. Januana, S. *et al.* Functional characterization of sucrose phosphorylase and *scrR*, a regulator of sucrose metabolism in *Lactobacillus reuteri*. *Food. Microbiol.* **36**, 432–439 (2013).
15. Shida, T., Mukaijo, K., Ishikawa, S., Yamamoto, H. & Sekiguchi, J. Production of long-chain levan by a *sacC* insertional mutant form *Bacillus subtilis* 327UH. *Biosci. Biotechnol. Biochem.* **66**, 1555–1558 (2002).
16. Ananthalakshmy, V. K. & Gunasekaran P. Overproduction of levan in *Zymomonas mobilis* by using cloned *sacB* gene. *Enzyme. Microb. Tech.* **25**, 109–115 (1999).
17. Branda, S. S., Chu, F., Kearns, D. B., Losick, R. & Kolter, R. A major protein component of the *Bacillus subtilis* biofilm matrix. *Mol. Microbiol.* **59**, 1229–1238 (2006).
18. Romero, D., Aguilar, C., Losick, R. & Kolter, R. Amyloid fibers provide structural integrity to *Bacillus subtilis* biofilms. *Proc. Natl. Acad. Sci. USA.* **107**, 2230–2234.
19. Westers, L., Westers, H. & Quax, W. J. *Bacillus subtilis* as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism. *Biochim. Biophys. Acta.* **1694**, 299–310 (2004).
20. Sloma, A. *et al.* Bacillopeptidase F of *Bacillus subtilis*: purification of the protein and cloning of the gene. *J. Bacteriol.* **172**, 5520–5521 (1990).
21. Wu, X. C. *et al.* Cloning, genetic organization, and characterization of a structural gene encoding bacillopeptidase F from *Bacillus subtilis*. *J. Biol. Chem.* **265**, 6845–6850 (1990).
22. Sloma, A., Ally, A., Ally, D. & Pero, J. Gene encoding a minor extracellular protease in *Bacillus subtilis*. *J. Bacteriol.* **170**, 5557–5563 (1988).
23. Sloma, A. *et al.* Gene encoding a novel extracellular metalloprotease in *Bacillus subtilis*. *J. Bacteriol.* **172**, 1024–1029 (1990).
24. Rufo, G. A. Jr., Sullivan, B. J., Sloma, A. & Pero, J. Isolation and characterization of a novel extracellular metalloprotease from *Bacillus subtilis*. *J. Bacteriol.* **172**, 1019–1023 (1990).
25. Sloma, A. *et al.* Cloning and characterization of the gene for an additional extracellular serine protease of *Bacillus subtilis*. *J. Bacteriol.* **173**, 6889–6895 (1991).
26. Tran, L., Wu, X. C. & Wong, S. L. Cloning and expression of a novel protease gene encoding an extracellular neutral protease from *Bacillus subtilis*. *J. Bacteriol.* **173**, 6364–6372 (1991).
27. Stahl, M. L. & Ferrari, E. Replacement of the *Bacillus subtilis* subtilisin structural gene with an *in vitro*-derived deletion mutation. *J. Bacteriol.* **158**, 411–418 (1984).
28. Wong, S. L., Price, C. W., Goldfarb, D. S. & Doi, R. H. The subtilisin E gene of *Bacillus subtilis* is transcribed from a sigma 37 promoter *in vivo*. *Proc. Natl. Acad. Sci. USA* **81**, 1184–1188 (1984).
29. Keller, K. L., Bender, K. S. & Wall, J. D. Development of a markerless genetic exchange system for *Desulfovibrio vulgaris* hildenborough and its use in generating a strain with increased transformation efficiency. *Appl. Environ. Microbiol.* **75**, 7682–7691 (2009).
30. Feng, J. *et al.* Metabolic engineering of *Bacillus amyloliquefaciens* for poly-gamma-glutamic acid ( $\gamma$ -PGA) overproduction. *Microb. Biotechnol.* **7**, 446–455 (2014).
31. Branda, S. S. *et al.* Genes involved in formation of structured multicellular communities by *Bacillus subtilis*. *J. Bacteriol.* **186**, 3970–3979 (2004).
32. Stanley, N. R. & Lazazzera, B. A. Defining the genetic differences between wild and domestic strains of *Bacillus subtilis* that affect poly- $\gamma$ -DL-glutamic acid production and biofilm formation. *Mol. Microbiol.* **57**, 1143–1158 (2005).
33. Dogsa, I., Brloznic, M., Stopar, D. & Mandic-Mulec, I. Exopolymer diversity and the role of levan in *Bacillus subtilis* biofilms. *PLoS One.* **8**, e62044 (2013).
34. Srikanth, R., Reddy, C. H. S. S., Siddhartha, G., Ramaiah, M. J. & Uppuluri, K. B. Review on production, characterization and application of microbial levan. *Carbohydr. Polym.* **120**, 102–114 (2015).
35. Wong, S. L., Ye, R. & Nathoo, S. Engineering and production of streptokinase in a *Bacillus subtilis* expression-secretion system, *Appl. Environ. Microbiol.* **60**, 517–523 (1994).
36. Wu, X. C., Lee, W., Tran, L. & Wong, S. L. Engineering a *Bacillus subtilis* expression-secretion system with a strain deficient in six extracellular proteases. *J. Bacteriol.* **173**, 4952–4958 (1991).
37. Wu, X. C., Ng, S. C., Near, R. I. & Wong, S. L. Efficient production of a functional single-chain antidigoxin antibody via an engineered *Bacillus subtilis* expression-secretion system, *Nat. Biotechnol.* **11**, 71–76 (1993).
38. Margot, P. & Karamata, D. The *wprA* gene of *Bacillus subtilis* 168, expressed during exponential growth, encodes a cell-wall-associated protease. *Microbiology.* **142**, 3437–3444 (1996).
39. Kawamura, F. & Doi, R. H. Construction of a *Bacillus subtilis* double mutant deficient in extracellular alkaline and neutral proteases. *J. Bacteriol.* **160**, 442–444 (1984).
40. Wu, S. C., Qureshi, M. H. & Wong, S. L. Secretory production and purification of functional full-length streptavidin from *Bacillus subtilis*. *Protein Expr. Purif.* **24**, 348–356 (2002).
41. Geng, W. T. *et al.* Complete genome sequence of *Bacillus amyloliquefaciens* LL3, which exhibits glutamic acid-independent production of poly- $\gamma$ -glutamic acid. *J. Bacteriol.* **193**, 3393–3394 (2011).
42. Feng, J. *et al.* Functions of poly-gamma-glutamic acid ( $\gamma$ -PGA) degradation genes in  $\gamma$ -PGA synthesis and cell morphology maintenance. *Appl. Microbiol. Biot.* **98**, 6397–6407 (2014).
43. Feng, J. *et al.* Curing the plasmid pMC1 from the poly ( $\gamma$ -glutamic acid) producing *Bacillus amyloliquefaciens* LL3 strain using plasmid incompatibility. *Appl. Biochem. Biotechnol.* **171**, 532–542 (2013).
44. Asgher, M., Javaid Asad, M., Rahman, S. U. & Legge, R. L. A thermostable  $\alpha$ -amylase from a moderately thermophilic *Bacillus subtilis* strain for starch processing. *J. Food. Eng.* **79**, 950–955 (2007).

45. Smith, K. & Youngman, P. Use a new integrational vector to investigate compartment-specific expression of the *Bacillus subtilis* *spoIIIM* gene. *Biochimie*. **74**, 705–711 (1992).
46. Zhang, W. *et al.* Chromosome integration of the *Vitreoscilla* hemoglobin gene (*vgb*) mediated by temperature-sensitive plasmid enhances  $\gamma$ -PGA production in *Bacillus amyloliquefaciens*. *FEMS. Microbiol. Lett.* **343**, 127–134 (2013).
47. Miller, G. Use of dinitrosalicylic acid reagent for determination of reducing sugars. *Anal. Chem.* **31**, 426–428 (1959).
48. Millet, J. Characterization of proteinases excreted by *Bacillus subtilis* Marburg strain during sporulation. *J. Appl. Bact.* **33**, 207–219 (1970).
49. Goto, A. & Kunioka, M. Biosynthesis and hydrolysis of Poly( $\gamma$ -glutamic acid) from *Bacillus subtilis* IFO3335. *Biosci. Biotech. Bioch.* **56**, 1031–1035 (1992).
50. Zhan, D. D. Determination of fructose in fruit juice based on UV-Photometric method. *J. Qiongzhou. Univ.* **10**, 23–27 (2003).

### Acknowledgments

This work was supported by the National Key Basic Research Program of China (“973” -Program) 2012CB725204, the National Key Technology Support Program 2015BAD16B04, the Natural Science Foundation of China Grant Nos. 31470213 and 31170030, and the Project of Tianjin, China (13JCZDJC27800, 13JCYBJC24900, 13TXSYJC40100 and 14ZCZDSF00009) and the Ph.D. Candidate Research Innovation Fund of Nankai University.

### Author Contributions

J.F. and C.J.S. designed the research. J.F., Y.Y.G. and Y.F.Q. performed the research. J.F., W.Z., W.X.G., C.Y. and S.F.W. analyzed the data. J.F. and M.F.C. wrote the paper. All of the authors reviewed the manuscript.

### Additional Information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Feng, J. *et al.* Recruiting a new strategy to improve levan production in *Bacillus amyloliquefaciens*. *Sci. Rep.* **5**, 13814; doi: 10.1038/srep13814 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>